FY2026 EPS Estimates for Novartis AG Boosted by Analyst (NYSE:NVS)

Novartis AG (NYSE:NVS) – Equities research analysts at Zacks Research upped their FY2026 earnings estimates for shares of Novartis in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $8.47 per share for the year, up from their prior forecast of $8.36. The consensus estimate for Novartis’ current full-year earnings is $7.13 per share.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, January 30th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Novartis had a return on equity of 29.90% and a net margin of 29.83%. The firm had revenue of $11.42 billion during the quarter, compared to analysts’ expectations of $11.69 billion. During the same quarter in the previous year, the firm earned $1.51 earnings per share.

A number of other equities analysts have also weighed in on the stock. Morgan Stanley started coverage on shares of Novartis in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $114.00 price objective for the company. BMO Capital Markets started coverage on shares of Novartis in a research note on Friday, February 23rd. They set a “market perform” rating and a $114.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novartis has a consensus rating of “Moderate Buy” and an average target price of $114.00.

Novartis Price Performance

Shares of NYSE NVS opened at $97.29 on Tuesday. Novartis has a twelve month low of $92.19 and a twelve month high of $108.78. The firm has a market cap of $198.86 billion, a P/E ratio of 13.55, a PEG ratio of 1.47 and a beta of 0.54. The company has a 50 day moving average of $97.95 and a 200 day moving average of $98.99. The company has a quick ratio of 0.93, a current ratio of 1.15 and a debt-to-equity ratio of 0.39.

Novartis Increases Dividend

The business also recently announced an annual dividend, which was paid on Thursday, March 7th. Shareholders of record on Friday, March 8th were paid a dividend of $3.7772 per share. The ex-dividend date was Thursday, March 7th. This is a positive change from Novartis’s previous annual dividend of $3.47. This represents a yield of 3.1%. Novartis’s payout ratio is currently 33.84%.

Institutional Investors Weigh In On Novartis

A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its position in shares of Novartis by 1.2% during the 4th quarter. Wellington Management Group LLP now owns 4,746,599 shares of the company’s stock valued at $479,264,000 after acquiring an additional 54,683 shares during the period. Principal Financial Group Inc. grew its position in shares of Novartis by 2.1% during the 3rd quarter. Principal Financial Group Inc. now owns 2,539,265 shares of the company’s stock valued at $258,650,000 after acquiring an additional 51,391 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Novartis by 50.4% during the 3rd quarter. Envestnet Asset Management Inc. now owns 2,049,901 shares of the company’s stock valued at $208,803,000 after acquiring an additional 686,847 shares during the period. Grantham Mayo Van Otterloo & Co. LLC grew its position in shares of Novartis by 167.6% during the 3rd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,827,263 shares of the company’s stock valued at $186,125,000 after acquiring an additional 1,144,307 shares during the period. Finally, Fisher Asset Management LLC grew its position in shares of Novartis by 2.4% during the 4th quarter. Fisher Asset Management LLC now owns 1,442,003 shares of the company’s stock valued at $145,599,000 after acquiring an additional 33,791 shares during the period. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.